Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (111-120 of 338) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2010
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinomaDaniel C Cho, Matthew B Cohen, David J Panka, et al.
Melanoma Research|May 5, 2011
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanomaErin R DeRose, Alexander Pleet, Wei Wang, et al.
Cancer|March 28, 2006
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyKen Wyman, Michael B Atkins, Victor Prieto, et al.
Melanoma Research|December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitorsCharlene M Mantia, Lillian Werner, Brian Stwalley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2019
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell CarcinomaDaniel C Cho, Matthew B Cohen, David J Panka, et al.
Clinical Genitourinary Cancer|October 23, 2013
Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinomaPeter Beddy, Elizabeth M Genega, Long Ngo, et al.
The Oncologist|November 11, 2023
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell CarcinomaRana R McKay, Katharina Leucht, Wanling Xie, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 18, 2014
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitutionJanice P Dutcher, Donna Neuberg, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer|September 25, 2019
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, et al.
Cancers|December 10, 2021
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer AnalysisDongyu Zhang, Neil J Shah, Michael Cook, et al.
Pageof 34

Showing results (111-120 of 338) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2010
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinomaDaniel C Cho, Matthew B Cohen, David J Panka, et al.
Melanoma Research|May 5, 2011
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanomaErin R DeRose, Alexander Pleet, Wei Wang, et al.
Cancer|March 28, 2006
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyKen Wyman, Michael B Atkins, Victor Prieto, et al.
Melanoma Research|December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitorsCharlene M Mantia, Lillian Werner, Brian Stwalley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2019
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell CarcinomaDaniel C Cho, Matthew B Cohen, David J Panka, et al.
Clinical Genitourinary Cancer|October 23, 2013
Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinomaPeter Beddy, Elizabeth M Genega, Long Ngo, et al.
The Oncologist|November 11, 2023
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell CarcinomaRana R McKay, Katharina Leucht, Wanling Xie, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 18, 2014
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitutionJanice P Dutcher, Donna Neuberg, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer|September 25, 2019
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, et al.
Cancers|December 10, 2021
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer AnalysisDongyu Zhang, Neil J Shah, Michael Cook, et al.
Pageof 34